EGFR and non-small cell lung carcinoma: Several phase 3 trials, including ADJUVANT trial (NCT01405079), will determine the efficacy of EGFR TKIs in the adjuvant treatment for complete resected early-stage NSCLC harboring activating EGFR mutations in the near future.